STAAR Surgical (NASDAQ:STAA - Get Free Report) major shareholder Broadwood Partners, L.P. bought 138,054 shares of the company's stock in a transaction dated Monday, April 7th. The stock was purchased at an average cost of $15.61 per share, for a total transaction of $2,155,022.94. Following the completion of the transaction, the insider now owns 13,332,264 shares of the company's stock, valued at $208,116,641.04. This represents a 1.05 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Broadwood Partners, L.P. also recently made the following trade(s):
- On Friday, April 4th, Broadwood Partners, L.P. acquired 497,631 shares of STAAR Surgical stock. The stock was purchased at an average cost of $15.91 per share, with a total value of $7,917,309.21.
- On Wednesday, April 2nd, Broadwood Partners, L.P. bought 31,780 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.43 per share, with a total value of $553,925.40.
- On Monday, March 31st, Broadwood Partners, L.P. purchased 22,189 shares of STAAR Surgical stock. The shares were acquired at an average cost of $17.46 per share, for a total transaction of $387,419.94.
- On Thursday, March 27th, Broadwood Partners, L.P. acquired 3,620 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.48 per share, with a total value of $63,277.60.
- On Tuesday, March 25th, Broadwood Partners, L.P. bought 34,296 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.44 per share, for a total transaction of $598,122.24.
- On Thursday, March 20th, Broadwood Partners, L.P. purchased 108,720 shares of STAAR Surgical stock. The shares were bought at an average price of $17.96 per share, with a total value of $1,952,611.20.
- On Tuesday, March 18th, Broadwood Partners, L.P. acquired 93,124 shares of STAAR Surgical stock. The stock was bought at an average price of $17.54 per share, for a total transaction of $1,633,394.96.
- On Monday, March 3rd, Broadwood Partners, L.P. bought 249,503 shares of STAAR Surgical stock. The shares were bought at an average cost of $16.64 per share, with a total value of $4,151,729.92.
- On Thursday, February 27th, Broadwood Partners, L.P. purchased 259,316 shares of STAAR Surgical stock. The stock was bought at an average cost of $17.05 per share, for a total transaction of $4,421,337.80.
- On Friday, February 14th, Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock. The shares were purchased at an average cost of $15.49 per share, with a total value of $565,880.68.
STAAR Surgical Price Performance
NASDAQ STAA opened at $16.14 on Tuesday. The company's fifty day moving average is $18.65 and its two-hundred day moving average is $24.55. STAAR Surgical has a 52-week low of $13.50 and a 52-week high of $52.68. The firm has a market capitalization of $796.11 million, a price-to-earnings ratio of -39.37 and a beta of 0.75.
Analyst Upgrades and Downgrades
STAA has been the subject of several research reports. Stephens reiterated an "equal weight" rating and set a $17.00 price target on shares of STAAR Surgical in a report on Tuesday, March 18th. Jefferies Financial Group downgraded shares of STAAR Surgical from a "buy" rating to a "hold" rating in a research report on Wednesday, February 12th. Mizuho downgraded shares of STAAR Surgical from an "outperform" rating to a "neutral" rating and cut their price target for the company from $45.00 to $17.00 in a report on Wednesday, February 12th. Canaccord Genuity Group decreased their price objective on shares of STAAR Surgical from $28.00 to $17.00 and set a "hold" rating for the company in a report on Thursday, February 13th. Finally, Piper Sandler cut their price objective on STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $25.29.
Read Our Latest Research Report on STAAR Surgical
Institutional Investors Weigh In On STAAR Surgical
Institutional investors have recently added to or reduced their stakes in the company. FMR LLC lifted its position in shares of STAAR Surgical by 79.3% in the 3rd quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier's stock worth $263,000 after acquiring an additional 3,136 shares during the period. HighTower Advisors LLC acquired a new position in shares of STAAR Surgical in the third quarter valued at $336,000. Quarry LP bought a new position in STAAR Surgical in the third quarter worth $50,000. State Street Corp boosted its stake in STAAR Surgical by 0.5% during the third quarter. State Street Corp now owns 1,940,567 shares of the medical instruments supplier's stock worth $72,092,000 after buying an additional 10,430 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in STAAR Surgical during the third quarter worth $508,000. 96.70% of the stock is owned by institutional investors and hedge funds.
About STAAR Surgical
(
Get Free Report)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
